What a 1990s biological experiment still teaches turf managers today

By the late 1990s, golf course management was in a period of experimentation.

Concerns about fungicide resistance, environmental scrutiny and rising costs were pushing superintendents to look beyond conventional chemistry. Integrated pest management was gaining credibility. Soil biology was becoming a buzzword. And into that moment came a company called EcoSoils Systems with a bold promise: disease control through biology, delivered directly through the irrigation system.

The platform was called BioJect. Beneficial microbes were injected via irrigation to establish populations capable of suppressing diseases such as brown patch, Pythium and dollar spot. It was marketed not as a product but as a biological management system — a fundamentally different way of thinking about turf health.

On paper, it made sense. It aligned with IPM principles. It appealed to progressive superintendents. And it showed up in Mid-Atlantic newsletter product guides and meeting materials throughout the late 1990s. BioJect was clearly on the industry’s radar.

But awareness is not the same as validation. 

When you go back through the archived Mid-Atlantic and trade publications, the most striking thing about BioJect is how little hard data exists. The strongest efficacy language amounts to a single phrase: “some success.” In one Mid-Atlantic newsletter, a course reported disease suppression following injection of bacteria via the BioJect system as part of a broader IPM program. That’s it.

No disease severity ratings. No untreated controls. No replication. No statistics. No multi-year follow-ups. No university trials. No peer-reviewed studies. No USGA-funded research summaries. No Green Section Record article evaluating results.

For a system that required thousands of dollars in equipment, inputs and labor, that absence matters.

The silence from the USGA Green Section is especially telling. Historically, when a new cultural practice proves repeatable, scalable and agronomically sound, it eventually finds its way into Green Section guidance. That didn’t happen with BioJect. Not because biological approaches were dismissed — the Green Section has long supported IPM and reduced-risk strategies — but because proof matters.

Silence, in this case, doesn’t equal rejection. It means the evidence never rose to a level where it could be responsibly recommended.

The same interpretation applies to how respected turf pathologists of the era treated BioJect. Peter Dernoeden, Ph.D., for example, was open-minded about biology and IPM but unwaveringly evidence-driven. BioJect appears in product listings and meeting materials, not in disease management recommendations. That’s not endorsement; it’s professional caution.

BioJect did not fail because biology is a dead end. It struggled because biology is inherently inconsistent, slow to establish and heavily influenced by the environment. Even today, with vastly improved formulations, sequencing tools and delivery systems, biological disease control in turf remains supplemental rather than standalone. In the 1990s, expecting irrigation-injected microbes to suppress disease across sites reliably was a tall order.

BioJect asked superintendents to make a leap of faith at a time when the science had not caught up to the vision.

Looking back, the investment calculus is straightforward — high upfront cost and limited independent validation. For most operations, that equation didn’t justify the expense. 

Today’s turf industry is once again awash in biological claims of microbes. Technology and science are stronger today, but the core question hasn’t changed: Where is the independent evidence?

We need to be open to the potential of biological solutions in turf management. However, it must be grounded in evidence, not optimism alone. That may be the most enduring lesson BioJect left behind.